MedTrace Logo

Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker

NCT03927573 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2023-07-10

No results posted yet for this study

Summary

This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM3PSCA in patients with prostate stem cell antigen (PSCA) expressing cancer types which failed to respond to standard therapy.

Conditions

Interventions

DRUG

GEM3PSCA

Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles

Sponsors & Collaborators

  • GCP-Service International Ltd. & Co. KG

    collaborator INDUSTRY

  • AvenCell Europe GmbH

    lead INDUSTRY

Principal Investigators

  • Ralf Bargou, Prof. Dr. · Universitätsklinikum Würzburg, Interdisziplinäres Studienzentrum mit ECTU

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-15
Primary Completion
2023-06-28
Completion
2023-06-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03927573 on ClinicalTrials.gov